Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598990 | 0.80 | ALDH1A1 (0.39) | ALDH1A1LMNACYP3A4CYP1A2CYP2C9 | |
| SCHEMBL597801 | 0.80 | ALDH1A1 (0.39) | ALDH1A1LMNACYP3A4CYP1A2CYP2C9 | |
| SCHEMBL3783239 | 0.80 | ALDH1A1 (0.39) | ALDH1A1LMNACYP3A4CYP1A2CYP2C9 | |
| SCHEMBL3783240 | 0.80 | ALDH1A1 (0.39) | ALDH1A1LMNACYP3A4CYP1A2CYP2C9 | |
| SCHEMBL25590294 | 0.73 | — | — | |
| SCHEMBL910279 | 0.73 | — | — | |
| SCHEMBL9167515 | 0.72 | — | — | |
| SCHEMBL20381172 | 0.70 | ALDH1A1 (0.35) | ALDH1A1LMNACYP3A4CYP1A2CYP2C9 | |
| SCHEMBL1411809 | 0.68 | APLNR (0.39) | ALDH1A1LMNACYP3A4CYP1A2CYP2C9 | |
| SCHEMBL6554381 | 0.68 | ALDH1A1 (0.34) | ALDH1A1LMNACYP3A4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022261427-A1 | (4-(6-((2-OCTAHYDROCYCLOPENTA[C]PYRROL-5-YL)AMINO)PYRIDAZIN-3-YL)PHENYL)(IMINO)(METHYL)-LAMBDA6- SULFANONE DERIVATIVES AND SIMILAR COMPOUNDS AS MUSCARINIC ACETYLCHOLINE RECEPTOR M4 ANTAGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | VANDERBILT UNIVERSITY (US) | 2022-12-15 | — | — | WO | disclosed |